In:
Mycoses, Wiley, Vol. 59, No. 9 ( 2016-09), p. 585-593
Abstract:
The second cause of death among systemic mycoses, cryptococcosis treatment represents a challenge since that 5‐flucytosine is not currently available in Brazil. Looking for alternatives, this study evaluated antifungal agents, alone and combined, correlating susceptibility to genotypes. Eighty Cryptococcus clinical isolates were genotyped by URA 5 gene restriction fragment length polymorphism. Antifungal susceptibility was assessed following CLSI ‐M27A3 for amphotericin ( AMB ), 5‐flucytosine (5 FC ), fluconazole ( FCZ ), voriconazole ( VRZ ), itraconazole ( ITZ ) and terbinafine ( TRB ). Drug interaction chequerboard assay evaluated: AMB + 5 FC , AMB + FCZ , AMB + TRB and FCZ + TRB . Molecular typing divided isolates into 14 C. deuterogattii ( VGII ) and C. neoformans isolates were found to belong to genotype VNI ( n = 62) and VNII ( n = 4). C. neoformans VNII was significantly less susceptible than VNI ( P = 0.0407) to AMB ; C. deuterogattii was significantly less susceptible than VNI and VNII to VRZ ( P 〈 0.0001). C. deuterogattii was less susceptible than C. neoformans VNI for FCZ ( P = 0.0170), ITZ ( P 〈 0.0001) and TRB ( P = 0.0090). The combination FCZ + TRB showed 95.16% of synergistic effect against C. neoformans genotype VNI isolates and all combinations showed 100% of synergism against genotype VNII isolates, suggesting the relevance of cryptococcal genotyping as it is widely known that the various genotypes (now species) have significant impact in antifungal susceptibilities and clinical outcome. In difficult‐to‐treat cryptococcosis, terbinafine and different antifungal combinations might be alternatives to 5 FC .
Type of Medium:
Online Resource
ISSN:
0933-7407
,
1439-0507
DOI:
10.1111/myc.2016.59.issue-9
Language:
English
Publisher:
Wiley
Publication Date:
2016
detail.hit.zdb_id:
2020780-3
Permalink
